DL-Pyroglutamic acid

DL-Pyroglutamic acid (CAS No.: 149-87-1) is a cyclized derivative of glutamic acid and a racemic mixture of D- and L-pyroglutamic acid that occurs as a metabolite in biological systems, representing an important small molecule scaffold in neurochemical and antiviral research. Functionally, it has been characterized as a surface inactivator of hepatitis B virus and demonstrates broad antiviral activity against enveloped viruses such as vaccinia virus, herpes simplex virus, and influenza virus, while showing limited effect on non-enveloped viruses like poliovirus, supporting its utility in studies of viral inactivation mechanisms and membrane-associated processes. In parallel, DL-pyroglutamic acid has been implicated in modulation of central nervous system signaling through potential inhibition of γ-aminobutyric acid transaminase, leading to elevated GABA levels and associated antiepileptic and neuromodulatory effects, positioning it within GABAergic pathway research. Although precise potency metrics are not consistently defined, its biological activity is typically observed in low micromolar to higher concentration ranges depending on the assay system. The compound has also been employed as a synthetic intermediate in the development of GABA-related peptides with antinociceptive properties and in behavioral pharmacology models, where derivatives have demonstrated effects in assays such as forced swim and thermal nociception tests. Additionally, altered levels of pyroglutamic acid enantiomers have been noted in certain pathological conditions, including renal dysfunction, further supporting its relevance as a metabolic biomarker. In experimental settings, concentrations or doses are selected according to specific in vitro or in vivo models, making DL-pyroglutamic acid a versatile tool for antiviral screening, neuropharmacological investigations, and metabolic studies.